Description
Niraparib, marketed under the brand name ZEJULA, It is an prescription medication that has been approved niraparib (ZEJULA) on March 27, 2017. The European Commission approved it on November 16, 2017, and Health Canada approved it on June 27, 2019.
What is ZEJULA (niraparib) ?
ZEJULA (niraparib) capsules, for oral use. U.S. Approval: 2017
ZEJULA is a poly(ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
How to order approved “ZEJULA (niraparib) for capsules” Medicine?
ZEJULA (Niraparib) is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing ZEJULA and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.





